Story · Medicine & Biotech

Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer

1 outlet · first reported by OncoDaily on

Cardiff Oncology announced on November 16, 2026, that the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab for first-line treatment of adults with KRAS- or NRAS-mutated metastatic (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer

    Cardiff Oncology announced on November 16, 2026, that the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab for first-line treatment of adults with KRAS- or NRAS-mutated metastatic

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.